Jump to main content
Jump to site search

Issue 17, 2018
Previous Article Next Article

Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma

Author affiliations

Abstract

Doxorubicin (DOX) is commonly used to treat human malignancies, and its efficacy can be maximized by limiting the cardiac toxicity when combined with nanoparticles. Here, we reported a unique type of reversibly disulfide cross-linked micellar formulation of DOX (DOX-DCMs) for the targeted therapy of B-cell lymphoma. DOX-DCMs exhibited high drug loading capacity, optimal particle sizes (15–20 nm), outstanding stability in human plasma, and stimuli-responsive drug release profile under reductive conditions. DOX-DCMs significantly improved the pharmacokinetics of DOX, and its elimination half-life (t1/2) and area under curve (AUC) were 5.5 and 12.4 times of that of free DOX, respectively. Biodistribution studies showed that DOX-DCMs were able to preferentially accumulate in the tumor site and significantly reduce the cardiac uptake of DOX. In a xenograft model of human B-cell lymphoma, compared with the equivalent dose of free DOX and non-crosslinked counterpart, DOX-DCMs not only significantly inhibited the tumor growth and prolonged the survival rate, but also remarkably reduced DOX-associated cardiotoxicity. Furthermore, the exogenous administration of N-acetylcysteine (NAC) at 24 h further improved the therapeutic efficacy of DOX-DCMs, which provides a “proof-of-concept” for precise drug delivery on-demand, and may have great translational potential as future cancer nano-therapeutics.

Graphical abstract: Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma

Back to tab navigation

Supplementary files

Publication details

The article was received on 24 Jan 2018, accepted on 23 Mar 2018 and first published on 27 Mar 2018


Article type: Paper
DOI: 10.1039/C8NR00680F
Citation: Nanoscale, 2018,10, 8207-8216
  •   Request permissions

    Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma

    K. Xiao, Q. Liu, N. Al Awwad, H. Zhang, L. Lai, Y. Luo, J. S. Lee, Y. Li and K. S. Lam, Nanoscale, 2018, 10, 8207
    DOI: 10.1039/C8NR00680F

Search articles by author

Spotlight

Advertisements